The EMERGE GHI advisory board comprises leading industry visionaries at the sharp edge of where health and technology are converging.
Partner, Sofinnova Partners
Edward Kliphuis joined Amadeus in 2020 focusing on European deeptech companies. Edward was previously at M Ventures, the €400m AUM corporate VC-arm of Merck KGaA, where he was responsible for health-tech, frontier-tech and sustainability investments.
Edward led, among others, the investments in Akili Interactive Labs (the first-ever FDA-approved prescription video-game); Wiliot (battery-free Bluetooth tags with infinite lifetime, enabling a true connected-everything), and Sonde Health (voice-analysis platform for health and wellness inferences for use on self-owned devices).
Prior to M Ventures, Edward was in the Life Sciences securities team at Kempen & Co, a pan-European merchant bank, covering listed small- and mid-cap Life Sciences equities. He started his career as an analyst within the biopharma investment team of M Ventures. Edward holds an MSc in Biopharmaceutical Sciences from Leiden University, the Netherlands, with a specialisation in pharmacology.
Managing Partner, 7wire Ventures
Lee Shapiro is Managing Partner at 7wireVentures, an investment firm he co-founded over a decade ago. He also served as Chief Financial Officer of Livongo Health until November 2020. Previously he was President of Allscripts from 2001 until the end of 2012. His leadership was integral in the execution of over $4B in mergers, acquisitions and financings. Prior to stepping in as CFO of Livongo and leading its 2019 IPO, Lee served on the board of the company since its launch, chairing the audit committee and as a member of its compensation committee.
Lee served on the board of directors (audit committee and nominating and governance committee) of Medidata Solutions until its sale in 2019 to Dassault Systèmes. He also served on the board of Tivity Health until May 2020, where he chaired the audit committee and also served on the compensation committee. Lee also serves on the board and committees of various 7wireVentures portfolio companies. For the past four years, he has been a member of the National Board of Directors of the American Heart Association, where he chairs the audit committee and serves on the business operations committee.
Mussaad Al Razouki
Chief Investment & BDO, Kuwait Life Sciences Company
Mussaad Al Razouki has over 15 years of experience in venture capital and private equity investment with a focus on healthcare and technology, shifting from an excellence in clinical practice and research to the management and financing of healthcare and education systems.
A graduate of Columbia Business School, Dr. Razouki is the first ever-Arab national to receive an MBA with a focus on Healthcare Management and Finance. An Oral and Maxillofacial surgeon by training, Dr Razouki has completed clinical rotations at New York Presbyterian Hospital of Columbia University Medical Center, Harlem Hospital, Cleveland University Hospital of Case Western Reserve University and Mass General Hospital of Harvard University.
Dr Razouki is currently working on the Middle East’s largest patient portal and is setting up a digital first home healthcare platform.
Lana Y. Ghanem
Managing Director, Hikma Ventures
Lana is the Managing Director of Hikma Ventures (the corporate
VC arm of Hikma Pharmaceuticals PLC) which she helped establish in 2015. Lana started her career at Hikma Pharmaceuticals PLC in 2012 as the Assistant to the CEO and Director of Corporate Strategy & Development where she worked on strategic projects across the company’s various functions including strategy, M&A, operations and finance. In addition, Lana co-founded the Innovation & Leadership Advisory Board (ILAB) at Hikma which consists of young Hikma employees whom share a dedication to advancing Hikma and ensuring it is at the frontier of innovation.
Prior to joining Hikma, Lana worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries.
Lana holds an MBA from Harvard Business School (HBS) and a Bachelors of Commerce degree from McGill University.
Francesca Domenech Wuttke
Chief Digital Officer, Almirall
Dr Wuttke is the chief digital officer of Almirall where she is developing and executing an end-to-end companywide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall. Dr Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 25 years of clinical, research, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia.
Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr Wuttke led Almirall’s Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Before that Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organization as well as managing the strategy and commercialization for the existing portfolio of cell therapy assets. Dr Wuttke holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
Founding Partner, Selvedge Venture
Alasdair Thong is the Founding Partner of Selvedge Venture and huge believer in how deep technology can have a fundamental impact across life sciences and healthcare. He has been part of the investment teams for six venture capital firms; Index Ventures, Medicxi, Leaps (Bayer AG), Mubadala Capital Ventures (the sovereign wealth fund of Abu Dhabi), Luminous Ventures and Ada Ventures, and holds advisory roles at a number of start-up companies and venture capital funds.
His investment expertise is focussed on the convergence of traditional tech and life sciences with a particular concentration on how artificial intelligence and machine learning techniques can be applied to solve healthcare and life sciences problems.
Alasdair graduated with an MPhil in Bioscience Enterprise from the University of Cambridge and holds a dual undergraduate degree in Law and Mandarin Chinese from the SOAS, University of London. He also spent time as a visiting student at Fudan University (Shanghai) and Beijing Normal University studying Mandarin Chinese.
Global Head of Digital, Almirall
Leading the externally focused digital innovation hubs and commercial teams in different locations in the world including Silicon Valley focusing on HealthTech innovation. with more than twelve years of experience in sales, marketing and digital marketing experience with global, emerging markets, Europe and the Middle East. founder of successfully exited start-ups with strong knowledge in the start-up community. He won different global awards including the European Excellence, Clio and Cannes Lions awards for different innovative projects like the first navigation application for visually impaired patients that is available on smart watches.
JOIN US IN DRIVING HEALTHCARE INNOVATION AND INVESTMENT
To apply to speak, or enquire about sponsorship please contact us using the form below.